Drugs / ABI-H3733
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04271592 | May → Nov 2020 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05414981 Comparator | Aug 2022 → Apr 2023 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2023-06-21 | Assembly Biosciences | Results Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023 assemblybio.com ↗ |
| 2023-06-07 | Assembly Biosciences | Results Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023 assemblybio.com ↗
Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors |
| 2023-03-22 | Assembly Biosciences | Results Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights assemblybio.com ↗
While the clinical antiviral activity seen in HBV patients receiving 3733 in our Phase 1b trial is impressive, our objective has always been to prioritize the strongest candidate in a data-driven manner. |
| 2022-12-19 | Assembly Biosciences | Results Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 assemblybio.com ↗ |
| 2022-06-22 | Assembly Biosciences | Results Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022 assemblybio.com ↗
Our enthusiasm for the new tablet formulation of 3733, which is being evaluated in our recently-initiated Phase 1b study, is supported by data presented today demonstrating improved PK parameters preclinically, with plasma levels comparable to the liquid formulation. |
| 2021-11-12 | Assembly Biosciences | Results Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio assemblybio.com ↗ |
| 2021-06-23 | Assembly Biosciences | Results Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021 assemblybio.com ↗
today announced data from its three clinical-stage core inhibitor programs, vebicorvir (VBR or ABI-H0731), ABI-H2158 (2158), and ABI-H3733 (3733), in an oral presentation and two poster presentations during the International Liver Congress™ 2021, |
| 2020-08-28 | Assembly Biosciences | Results Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020 assemblybio.com ↗
At the 300-mg dose, the mean decline from baseline to day 15 in HBV DNA and pgRNA levels were 2.5 log 10 IU/mL and 2.3 log 10 U/mL, respectively. |
| 2019-04-11 | Assembly Biosciences | Results Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 assemblybio.com ↗
ABI-H3733 demonstrated enhanced potency in preclinical studies |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-H3733 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05414981 ↗ |
| Route | Oral | “ABI-H3733 liquid oral dosage form” NCT04271592 ↗ |